2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Bioinformatics, Treatment Considerations, Therapy Sequence, Biological Processes, Pathogenesis, Hematopoiesis, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Platelet Disorders, Thrombocytopenias, Thrombotic Disorders, Immunology, Autoimmune Disorders, Infectious Diseases, Research, Fundamental Science, Translational Research, Study Population, Human
PAPER

1231 Mitochondrial function regulates age-associated platelet dysfunction and thrombosis

Angelina Kendi, Andrea Jardini, PhD2, Gowtham Annarapu, PhD3, Krithika Rao, PhD4, Deirdre Nolfi-Donegan, MD5, Sruti Shiva, PhD6
1 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States
2 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States
3 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States, University Of Pittsburgh, Pittsburgh, Pennsylvania, United States
4 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States, University Of Pittsburgh, Pittsburgh, Pennsylvania, United States
5 Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
6 Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States, University Of Pittsburgh, Pittsburgh, Pennsylvania, United States, University Of Pittsburgh, Pittsburgh, Pennsylvania, United States

Background: Thrombosis underlies major cardiovascular diseases including stroke, myocardial infarction, and deep vein thrombosis, which accounts for one in four deaths globally. While it is well-established that the risk for thrombosis increases exponentially with age, the mechanisms underlying this increased risk remain unclear. Circulating platelets are central to thrombus formation, and prior studies show platelet activation and aggregation increases with age. However, the molecular mechanisms underlying age-dependent platelet dysfunction and whether this dysfunction contributes to age-dependent increased thrombotic risk is unknown. Although anucleate, platelets contain metabolically active mitochondria that regulate platelet function. Our lab previously reported that mitochondrial bioenergetics are altered in platelets from aged people. Preliminary data now shows that mitofusin-1 (MFN1), a small GTPase that catalyzes outer mitochondrial membrane fusion, is decreased in human platelets from aged individuals compared to those from young. However, whether MFN1 drives mitochondrial dysfunction with age is unknown. We hypothesize that an age-dependent decrease in platelet MFN1 protein levels regulates mitochondrial function, driving platelet activation and thrombosis.

Methods: Platelets were isolated from healthy young (18-35 years) and aged (>75 years) humans and young (12 weeks) and aged (1.5 years) mice. Platelet activation (activated glycoprotein IIβ/IIIα) was measured by assessing PAC1 binding via flow cytometry. Mitochondrial fission/fusion proteins (including MFN1) were measured by Western blot. Mitochondrial function was determined using MitoSOX oxidation assay and Seahorse XF analyzer for mitochondrial reactive oxygen species (mtROS) production and bioenergetics measurements, respectively. To mechanistically test the role of platelet MFN1, C57BL/6-PF4-icre male mice were crossed with B6.129(Cg)-MFN1tm1Dcc/J female mice to create platelet-specific MFN1 knockout (pMFN1-KO) mice. These mice (12 weeks and 1.5 years old) were then subjected to a ferric-chloride (FeCl3)-induced vascular injury model of thrombosis, in which FeCl3 was placed on the carotid artery, and blood flow was monitored by Laser Doppler to measure time to complete thrombotic occlusion. Additionally, platelets were isolated from these mice, and platelet activation and mitochondrial functional parameters were measured.

Results: We found that platelets from aged humans showed significantly increased platelet activation and a concomitant decrease in platelet MFN1 protein levels. At the mitochondrial level, we demonstrate that platelets from aged humans show a significant change in bioenergetics characterized by lower ATP-linked respiration as well as elevated mtROS production. These age-dependent alterations were recapitulated in young and aged mice platelets. To determine whether MFN1loss drives mitochondrial and platelet functional changes, we utilized pMFN1-KO mice. Young pMFN1-KO mice showed elevated mtROS production and platelet activation compared to young WT mice, phenocopying aged WT mice. Young pMFN1-KO mice and aged WT mice showed a significantly decreased time to thrombotic occlusion compared to young WT mice when subjected to a FeCl3-induced vascular injury model compared to wildtype.

Conclusion: These data reveal a novel mechanism in which platelet MFN1 and mtROS modulate age-dependent platelet dysfunction and thrombosis. Further, this study identifies MFN1 as a unique therapeutic target which is potentially specific to age-dependent thrombosis.

Gowtham Annarapu, PhD: No relevant conflicts of interest to declare.